Drug Trial Radar · NCT04240886
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
Jan 4, 2020
Primary completion
Mar 29, 2022
Study completion May 9, 2022
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Jan 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
Conditions
- Invasive Fungal Infections
Interventions
fosmanogepixDrug
IV and oral fosmanogepix
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42Time frame: After first dose on Day 1 through Day 42
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
IP Address : City of Hope Investigational Drug Services (IDS)
Duarte, California
Duke Department of Pharmacy/Investigational Drug Service (IDS)
Durham, North Carolina
Duke Medicine Pavilion
Durham, North Carolina
Duke University Medical Center (Duke South Clinic)
Durham, North Carolina
Duke University Medical Center(Duke Hospital)
Durham, North Carolina
Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases
Brussels, Belgium
UZ Leuven - Department of Haematology
Leuven, Belgium
CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit
Yvoir, Belgium
Universitätsmedizin der Johannes Gutenberg-Universität Mainz III
Mainz, Germany
Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie
München, Bavaria, Germany
Pharmacy
Haifa, Israel
Rambam Medical Center
Haifa, Israel
Pharmacy
Ramat Gan, Israel
Sheba Medical Center, Tel Hashomer
Ramat Gan, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.